Tests mirabegron and tadalafil for blood sugar control in prediabetes
Tests two drugs against placebo in adults with prediabetes and obesity for 14 weeks.
Key facts
- Who runs it
- Philip Kern
- Where
- Lexington, United StatesSee the site
- Trial code
- Registry title
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 96 people, planned
- Started
- 13 Dec 2021
- Expected to end
- Jan 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mirabegron 50 MG
- Tadalafil 10 MG
- Placebo
- Record updated
- 31 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with prediabetes and overweight or obesity. It tests mirabegron, tadalafil, or both, compared with a placebo, for 14 weeks.
- Age
- 35 to 65 years
- Sex
- Women and men can join
- Disease stage
- Prediabetes: hemoglobin A1C between 5.7 and 6.4, and body mass index between 27 and 45
- Earlier treatment
- People who take antidiabetic medicines long-term, steroids, daily NSAIDs or anticoagulants cannot join
- Biomarker or test result
- Hemoglobin A1C between 5.7 and 6.4
Main reasons for not taking part
- Diabetes
- Long-term use of any antidiabetic medicines
- Any unstable medical condition
- Use of steroids, daily NSAIDs or anticoagulants
- History of chronic inflammatory conditions
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Hemoglobin A1C between 5.7 and 6.4
- Body mass index between 27 and 45
Who cannot take part
- Chronic use of any antidiabetic medications
- Use of steroids or daily use of NSAIDS
- Diabetes
- Any unstable medical condition
- History of chronic inflammatory conditions
- Any condition deemed risky by the study physician
- Use of anticoagulants
- Contraindications to the use of mirabegron or tadalafil
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Where in United States
- University of KentuckyLexington, United StatesContact: Zach LeichtTaking people
About the trial
What the trial wants to find out
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
The 4 groups in the trial
- Mirabegron (M)Treatment being tested
Drug will be administered for 12 weeks after baseline procedures.
Treatment: Mirabegron 50 MG
- Tadalafil (T)Treatment being tested
Drug will be administered for 12 weeks after baseline procedures.
Treatment: Tadalafil 10 MG
- Mirabegron and Tadalafil (MT)Treatment being tested
Both drugs will be administered for 12 weeks after baseline procedures.
Treatment: Mirabegron 50 MG and Tadalafil 10 MG
- Placebo (P)Placebo, for comparison
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
- Plain-language title
- Tests mirabegron and tadalafil for blood sugar control in prediabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05051436, who can take part
- Record updated
- 31 August 2026